[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614659":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":15,"responsibleParty":35,"collaborators":37,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":18,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Retrospective Cohort",null,"150 patients operated for non-recurrent meningioma between 2008 and 2016.",{"label":13,"type":10,"description":14,"interventionNames":10},"Prospective Cohort","60 patients diagnosed with meningioma recruited prospectively.",[16],{"facility":17,"status":18,"city":19,"state":10,"zip":10,"country":20,"countryCode":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Fondazione IRCCS Istituto Neurologico Carlo Besta","RECRUITING","Milan","Italy","IT",{"type":23,"coordinates":24},"Point",[25,26],12.59836,42.78235,{"lat":26,"lon":25},[29],{"name":30,"role":31,"phone":32,"phoneExt":33,"email":34},"Francesco Di Meco, MD","CONTACT","+ 39 02.2394","2400","francesco.dimeco@istituto-besta.it",{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[38,40],{"name":39,"class":6},"University of Milan",{"name":41,"class":6},"Università degli Studi del Piemonte Orientale Amedeo Avogadro","100614659","epigenetic-profiling-and-liquid-biopsy-perspectives-for-personalized-medicine-in-meningioma-patients---mind-100614659",false,"NCT07282470","Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND","Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients","MIND","Inclusion Criteria:\n\nInclusion Criteria (Retrospective \\& Prospective):\n\n* Patient aged 18 years or older.\n* First diagnosis of uni-focal meningioma of the convexity.\n* Macroscopical total resection (Simpson 1-3).\n\n(Retrospective only):\n\n* Surgery performed between 2007 and 2016;\n* availability of FFPE sample and medical records.\n\nExclusion Criteria:\n\n* Genetic syndromes.\n* Diffuse Meningeal Meningiomatosis.\n* Patients who underwent experimental treatment in neo-adjuvant setting.\n\n(Prospective only):\n\n* Previous surgical\u002Fmedical treatment for another meningioma;\n* positive oncological history (e.g., breast cancer).","ALL","18 Years",{"count":53,"type":54},210,"ESTIMATED","OBSERVATIONAL","Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma\u002FEVs).",[58,59],"Meningioma","Meningioma of Brain",[58,61],"Machine Learning","2026-02-09",{"date":64,"type":65},"2026-02-10","ACTUAL",{"date":67,"type":65},"2024-09-25",{"date":69,"type":54},"2026-03",{"name":5,"class":6},1]